



One Test for a Clean Bill of Urological Health

Cysto One PAP™

genetic molecular urine test

Boost effectiveness of patient testing

Urinary Tract Infections (UTIs) account for 83 million doctor visits, 1 million emergency department (ED) visits, and 100,000 hospitalizations annually with an estimated cost of \$1 billion annually in the US. Annually, there are over 84,000 new diagnoses of bladder cancer in the U.S.A and 430,000 globally, making it the fourth most prevalent malignancy in men and the fifth most prevalent in woman. Prognosis and mortality is strongly correlated with cancer staging at the time of diagnosis.

The Cysto One PAP is a molecular test to screen and diagnose low and high grade urinary bladder malignancies as well as urinary tract infections and sexually transmitted diseases.

Provide your patients with a streamlined screening experience by administering one simple test that encompasses a molecular PAP while accounting for a range of other harmful conditions.

Early screening is crucial to survival. As with other cancers, if we can identify a molecular marker with high sensitivity and specificity for urinary bladder neoplasms. We can change the course of the disease. Survival rates can jump from near hopelessness to a happy ending with little interruption. Patients need to be tested as clinically indicated.

Why Cysto One PAP?

The Cysto One PAP screens for presence of Cytokeratin 17. Keratin 17 is an immunobiomarker which is involved in the replication cycle of malignant cells. Presence of keratin 17 is a highly specific immunobiomarker for presence of urinary bladder malignancy. In addition Cysto One PAP is design to test for a host of other infectious urological conditions.

One Simple Test

Unlike urine cytology only, Cysto One PAP is a molecular comprehensive test that provides an overall assessment of urological health.

Early Detection

The Cysto One PAP detects cell abnormalities and specific immunobiomarkers for the presence of malignant urothelial cells that increase the odds of existing and developing urothelial bladder cancer – enabling more targeted monitoring of at-risk patients with hematuria.

Prevent Permanent Damage

Prognosis and mortality is strongly correlated with cancer staging at the same time of diagnosis. Muscle invasive malignancies at the time of diagnosis can result in a 60% 5 year survival rate.

value for your practice


educating patients

We recommend that men and women presenting with micro/macro hematuria be given the Cysto One PAP test. We strive to be a partner with you in this effort and will provide you all the necessary tools to create value for your patients and your practice, such as:

- A patient education flyer that explains the importance of the screen and what to expect via results.
- A consent form for the patient to sign so refusals can be placed in their file.
- A negative letter if patients results are negative PCG Molecular will send your patient a letter via email within 3 business days.

What is the procedure like?

The patient experience is a non-invasive voided urine collection done at the point of care doctor's offices. To self collect this urine specimen, instructions are provided for the patient and or medical provider that explains step by step the collection procedure.



helping you communicate lab results

for negative results

PCG Molecular will send your patients an email on your behalf within 3 business days if patient results are negative.

for “watch” or high risk results

Being placed on a watch is no reason for patients to panic. It doesn't mean they have bladder cancer or that they will ever get them. All it means is that we need to watch their cases more closely. We will send you a report and give you a sample letter to send to your patients that communicates the results and what next steps to follow.

for positive results

You will receive a detailed report for those patients that test positive for precancerous or cancerous cells, or urinary tract infections/ sexually transmitted infections. These patients may require additional tests, along with a personal call. We can advise you of next steps and referrals if you need them.

PCG Molecular is a preventive care diagnostic company re-engineering the way we approach health care. The pioneering company is dedicated to the development of molecular genetic screens that detect early signs of DNA and cellular damage.